Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Steroid-dependent nephrotic syndrome (SDNS) carries a high risk of toxicity from steroids or steroid-sparing agents. This open-label, randomized controlled trial was designed to test whether the monoclonal antibody rituximab is non-inferior to steroids in maintaining remission in juvenile forms of SDNS and how long remission may last (EudraCT:2008-004486-26).
Methods: We enrolled 30 children 4-15 years who had developed SDNS 6-12 months before and were maintained in remission with low prednisone doses (0.1-0.4 mg/Kg/day). Participants were randomized following a non-inferiority design to continue prednisone alone (n 15, controls) or to add a single intravenous infusion of rituximab (375 mg/m, n 15 intervention). Prednisone was tapered in both arms after 1 month. Children assigned to the control arm were allowed to receive rituximab to treat disease relapse.
Results: Proteinuria increased at 3 months in the prednisone group (from 0.14 to 1.5 g/day) (p < 0.001) and remained unchanged in the rituximab group (0.14 g/day). Fourteen children in the control arm relapsed within 6 months. Thirteen children assigned to rituximab (87%) were still in remission at 1 year and 8 (53%) at 4 years. Responses were similar in children of the control group who received rituximab to treat disease relapse. We did not record significant adverse events.
Conclusions: Rituximab was non-inferior to steroids for the treatment of juvenile SDNS. One in two children remains in remission at 4 years following a single infusion of rituximab, without significant adverse events. Further studies are needed to clarify the superiority of rituximab over low-dose corticosteroid as a treatment of SDNS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00467-020-04540-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndrome.
Clin Exp Nephrol
September 2025
Department of Pediatrics, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Background: Maintenance therapy using immunosuppressive agents after rituximab can be effective for sustaining remission in childhood-onset refractory frequently relapsing nephrotic syndrome/steroid-dependent nephrotic syndrome (FRNS/SDNS). We evaluated the long-term outcome of mycophenolate mofetil (MMF) after rituximab.
Methods: We conducted a multicenter, retrospective cohort study of patients with childhood-onset refractory FRNS/SDNS who received MMF as maintenance therapy after a single dose of rituximab and were followed up ≥ 2 years at three pediatric renal centers.
Response predictors and long-term outcomes of preprandial single-daily cyclosporine in children with steroid-dependent nephrotic syndrome.
J Nephrol
September 2025
Department of Pediatrics, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Background: Although single-daily cyclosporine may offer an effective therapeutic option with increased compliance and reduced nephrotoxicity, response predictors and long-term outcomes following this regimen remain unclear in children with steroid-dependent nephrotic syndrome.
Methods: A retrospective study was conducted between October 2005 and December 2021 on children with steroid-dependent nephrotic syndrome caused by minimal change disease (MCD) who were treated with preprandial single-daily cyclosporine to maintain 2-h post-dose levels of 500-700 ng/mL. The primary endpoint was the time to treatment failure after single-daily cyclosporine initiation.
Endothelial Dysfunction in Children with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome.
Indian J Nephrol
September 2024
Department of Biochemistry, Lady Hardinge Medical College, New Delhi, India.
Background: Children with frequently relapsing (FR) or steroid-dependent (SD) nephrotic syndrome (NS) show endothelial dysfunction and risk of endothelial injury during relapses, increasing the risk of accelerated atherosclerosis and adverse cardiovascular events. This study examines the plasma levels of markers of endothelial dysfunction [sE-selectin and vascular cell adhesion molecule-1 (VCAM-1)] in children aged 1-16 years with FRNS and SDNS in relapse.
Materials And Methods: Fifty-six children with FRNS and SDNS between 1 and 16 years were enrolled at the time of relapse and followed till six weeks of steroid-induced remission.
Rituximab-Induced Serum Sickness in a Seven-Year-Old Child With Nephrotic Syndrome.
Cureus
July 2025
Pediatrics, Facultad de Medicina, Universidad de la República, Montevideo, URY.
The aim of this article is to report an unusual side effect of rituximab in a child. We describe a seven-year-old boy with steroid-dependent nephrotic syndrome who presented with fever and severe polyarthralgia after his first dose of rituximab. The onset of symptoms 13 days after rituximab administration, the self-limited evolution of symptoms, the exclusion of other causes, and the presence of similar reports led to the diagnosis of rituximab-induced serum sickness as a possible adverse reaction.
View Article and Find Full Text PDFObinutuzumab, an Anti-CD20, in Refractory Adult Autoimmune Podocytopathies: Report of 2 Cases.
Kidney Med
September 2025
Department of Nephrology, Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-lès-Nancy, France.
Autoimmune podocytopathies can represent a therapeutic challenge in the case of frequently relapsing nephrotic syndrome leading to steroid dependence or steroid resistance. Rituximab is an effective treatment option, but allergic reactions or resistance to treatment are frequent. The first case describes a 32-year-old man with corticosteroid-dependent nephrotic syndrome since childhood.
View Article and Find Full Text PDF